Premium
Ikena Oncology Inc (IKNA)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -7.58620689655 | 1.45 | 1.51 | 1.34 | 46429 | 1.40408533 | CS |
| 4 | -0.2 | -12.987012987 | 1.54 | 1.558 | 1.26 | 80699 | 1.40547003 | CS |
| 12 | -0.26 | -16.25 | 1.6 | 1.94 | 1.26 | 243090 | 1.56455104 | CS |
| 26 | -0.38 | -22.0930232558 | 1.72 | 1.94 | 1.26 | 144590 | 1.59628925 | CS |
| 52 | -0.07 | -4.96453900709 | 1.41 | 1.94 | 1.22 | 195516 | 1.56967184 | CS |
| 156 | -4.82 | -78.2467532468 | 6.16 | 8.99 | 1.02 | 174961 | 2.77570189 | CS |
| 260 | -21.06 | -94.0178571429 | 22.4 | 37.61 | 1.02 | 169618 | 5.54222862 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
